




6th International Conference

HUS

& related disorders

Current diagnosis and therapy of
hemolytic uremic syndrome (HUS),
and related disorders

in cooperation with HOROS  doctoral programme



USEFUL INFORMATION

DEADLINE for Abstracts: **April 15, 2017**

REGISTRATION under: **www.hus-online.at**

Registration fees:

	until 31.05.17	after 01.06.17
Regular fee	300 €	350 €
Residents in training	200 €	250 €
Students & accomp.P.	100 €	150 €

Registration fee includes:

all meals, coffee breaks, welcome reception & Tyrolean gala dinner

For further details contact:

Reinhard.Wuerzner@i-med.ac.at

or

www.hus-online.at

VENUE

The venue is situated again in Igls, a small and beautiful village next to Innsbruck.

Address: Congresspark Igls, Eugenpromenade 2, A-6080 Igls, +43 512 377364,

<http://www.cmi.at/en/congresspark-igls.html>

It is an innovative light-infused glass building surrounded by meadows and forests and a stunning mountain view.

TRAVEL

Igls is a 15 or 20 minute bus or tram or taxi ride away from Innsbruck Airport or Central Railway station, respectively.

Innsbruck and Igls are well connected with public transport:

- Streetcar: Line 6
- Bus: J, N7, 4132 and 4141

Flights are usually much cheaper to/from Munich Airport (MUC),

which is 190 km away. From there take a pre-booked Four-Seasons-Taxi

(<https://www.tirol-taxi.at>) for 79 Euro (return, directly to/from your hotel, ~3h)

- mention "HUS" to get the cheap fare).

ACCOMMODATION

Several (but still limited) single and double rooms have been reserved for the participants in the vicinity of the congress at:

SPORTHOTEL IGLS (10 min by foot): 102 EUR incl. breakfast (174 EUR for two)

EAGLES INN (15 min by foot): 95 EUR incl. breakfast (120 EUR for a suite)

mention "HUS" to get the cheap fare).

Furthermore, Innsbruck offers a wide range of hotels, and public transport makes it easy to commute to Igls.

Sunday, June 11

10:00-18:30 Registration open

12:45 Welcome

I. Atypical hemolytic uremic syndrome (aHUS)

Chairs:

13:00 L1 aHUS – Role of complement and surface recognition
S. Meri, FI

13:30 L2 aHUS – Role of lectin pathway & coagulation, update
P. Garred, DK

14:00 L3 aHUS – Role of endothelial cells
M. Riedl, CA

14:30 FC1

14:45-15:15 Coffee break

II. HUS & related disorders

Chairs:

15:15 L4 aHUS – spectrum of involved molecules & mutations
M. Lemaire, CA

15:45 L5 C3G: Pathology and characterization of the deposits
S. Sethi, US

16:15 L6 Genetics of C3G
R.J. Smith, US

16:45 FC2

17:00-17:30 Coffee break

I. E. coli associated Hemolytic uremic syndrome (eHUS)

Chairs:

17:30 L7 EHEC in Europe – with a look back to the O104:H4 outbreak
H. Karch, DE

18:00 L8 Cytotoxic action of Shigatoxin on human erythrocyte progenitor cells
J. Müthing, DE

18:30 L9 Shiga toxin effects
M. Brigotti, IT

19:00 Welcome reception at the Congresspark Igls

Monday, June 12

IV. E. coli associated hemolytic uremic syndrome (eHUS) & complement

Chairs:

- | | | |
|-------|-----|--|
| 08:30 | L10 | Podocytes and anaphylatoxins
<i>M. Morigi, IT</i> |
| 09:00 | L11 | Complement control proteins and coagulation
<i>D. Orth-Höller, AT</i> |
| 09:30 | L12 | eHUSc – a new eHUS network
<i>N. van de Kar, NL</i> |

10:00-10:30

Coffee break

V. Algorithms of investigations in HUS

Chairs:

- | | | |
|-------|-----|---|
| 10:30 | L13 | Algorithm of complement lab investigations, quality control
<i>Z. Prohászka, HU</i> |
| 11:00 | L14 | Indication & interpretation of genetic analysis for aHUS patients
<i>S. Rodriguez de Cordoba, ES</i> |
| 11:30 | FC3 | Algorithm of investigations in non-first world countries
<i>H. Safouh, EG</i> |
| 11:45 | FC4 | Illustrative case presentation for aHUS differential diagnosis
<i>C. Bereczki, HU</i> |

12:00-13:00

Lunch break

13:00 Poster session with dessert

Chairs A/B/C

VI. Short communications, cases

Chairs:

- | | |
|-------|-----|
| 14:30 | FC5 |
| 14:45 | FC6 |
| 15:00 | FC7 |
| 15:15 | FC8 |

15:30-16:00

Coffee break

VII. Treatment and monitoring with Eculizumab

Chairs:

- | | | |
|-------|-----|--|
| 16:00 | L15 | Mode of action of eculizumab
<i>G.R. Andersen, DK</i> |
| 16:30 | L16 | Treatment of aHUS with eculizumab – update
<i>C. Bedrosian, Alexion Pharmaceuticals, US</i> |
| 17:00 | L17 | Monitoring eculizumab therapy & discontinuation
<i>G. Ardissino, IT</i> |

19:00

Tyrolean night at Patscherkofel

Tuesday, June 13

VII. Animal models & Treatment without complement inhibitors

Chairs:

08:30	L18	Novel C3 gain of function mouse model of aHUS <i>K. Marchbank, UK</i>
09:00	L19	Treatment of anti-factor H-associated HUS <i>A. Bagga, IN</i>
09:30	FC9	
09:45	FC10	

10:00-10:30

Coffee break

VIII. Treatment & monitoring using novel drugs

Chairs:

10:30	L20	Novel complement inhibitors, advantages & disadvantages <i>T.E. Mollnes, NO</i>
11:00	L21	Treatment using CR2-FH <i>M. Ruseva, UK</i>
11:30	L22	The therapeutic potential of LMW orally bioavailable AP inhibitors <i>R.A. Harrison, CH</i>
12:00		Concluding remarks <i>R. Würzner, AT</i>

12:15-14:00

Farewell and lunch

Platinsponsor:

